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There is a growing demand for production of recombinant proteins of many structural varieties in mammalian 
expression systems, either as therapeutics or for protein characterisation. However, certain recombinant proteins 
are “difficult to express” in mammalian expression systems requiring extensive cell line and process optimisation  
which, as a result, can have significant consequences for drug development processes. The Tissue Inhibitors of 
Metalloproteinase (TIMP) protein family, TIMP-2, -3 and -4, are naturally secreted proteins that share significant 
structural homology (~50% identity and ~70% similarity in amino acid sequence), but show profound differences 
in secretion in mammalian expression systems. Computational sequence analysis of the TIMPs shows areas of 
significant amino acid difference mainly locating to flexible loop regions. This study has investigated the molecular 
mechanisms that selectively restrict expression of recombinant proteins of extensive sequence similarity. The loci 
of the molecular steps that limit successful expression have been defined by quantitative real-time polymerase 
chain reaction, proteomic analyses, cellular fractionation and immunofluorescence microscopy. All three TIMPs 
were readily detectable at mRNA and protein level within the cell but only TIMP-2 was secreted effectively into 
the culture medium. Analysis of protein localisation showed intracellular protein for all three TIMPs, mainly co-
localised in the organellar and cytoskeleton fractions. In addition, immunofluorescence microscopy showed all 
three TIMPs to be detectable within the endoplasmic reticulum. TIMP-3, which was not secreted, was detected 
within the cell in both expected glycosylated and non-glycosylated forms. Treatment of intracellular TIMP-3 with 
glycosidases suggests the presence of an immature high mannose glycoform. Knockout of the TIMP-3 glycan site 
did not result in secretion. These data suggest that the post-translational processing of poorly expressed TIMPs 
limits transit through the secretory pathway. To overcome this challenge, cell engineering of limiting secretory 
pathway components could enhance production of these “difficult to express” recombinant proteins. 
 
 
 
 
 
